Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "upadacitinib"

10 News Found

FDA approves AbbVie’s Upadacitinib for treatment of inflammatory bowel disease
Drug Approval | October 14, 2025

FDA approves AbbVie’s Upadacitinib for treatment of inflammatory bowel disease

Updated indication expands treatment options for patients with ulcerative colitis and Crohn’s disease when tumor necrosis factor (TNF) blockers are clinically inadvisable


AbbVie announces positive topline results from second Phase 3 UP-AA trial evaluating Upadacitinib
News | August 23, 2025

AbbVie announces positive topline results from second Phase 3 UP-AA trial evaluating Upadacitinib

The safety profile in alopecia areata was generally consistent with that in approved indications, and no new safety signals were identified in this study


AbbVie announces positive Phase 3 results for Upadacitinib in Alopecia Areata
Clinical Trials | August 06, 2025

AbbVie announces positive Phase 3 results for Upadacitinib in Alopecia Areata

The average baseline SALT score was 83.8, indicating about 16% scalp hair coverage


AbbVie's phase 3 Select -GCA study of Upadacitinib showed positive results in patients with giant cell arteritis
News | April 23, 2024

AbbVie's phase 3 Select -GCA study of Upadacitinib showed positive results in patients with giant cell arteritis

Open a printable version of this pageEmail the URL of this page to a friend


Lancet publishes results of Phase 3 programmes of Rinvoq in Ulcerative Colitis
Biotech | May 27, 2022

Lancet publishes results of Phase 3 programmes of Rinvoq in Ulcerative Colitis

Data from the three studies formed the basis of the company's application for approval by regulatory agencies


AbbVie showcases its leadership in Rheumatology research with new data across multiple inflammatory joint diseases
Biotech | May 24, 2022

AbbVie showcases its leadership in Rheumatology research with new data across multiple inflammatory joint diseases

The hybrid congress will take place from 1-4 June in Copenhagen, as well as virtually


CHMP recommends European Commission approval of Rinvoq
Drug Approval | May 23, 2022

CHMP recommends European Commission approval of Rinvoq

Ulcerative colitis is a chronic, immune-mediated inflammatory bowel disease that can lead to substantial burden and often disability among patients


USFDA approves Rinvoq as an oral treatment for ankylosing spondylitis
Drug Approval | May 01, 2022

USFDA approves Rinvoq as an oral treatment for ankylosing spondylitis

The USFDA approval in AS marks the fifth indication for Rinvoq in chronic immune-mediated diseases


AbbVie and Allergan Aesthetics to present new research at 2022 AAD annual meeting
Biotech | March 22, 2022

AbbVie and Allergan Aesthetics to present new research at 2022 AAD annual meeting

Twelve abstracts and two late-breaking presentations demonstrate AbbVie and Allergan Aesthetics' shared commitment to advancing research across a spectrum of dermatologic conditions and aesthetic indications


USFDA approves Rinvoq for ulcerative colitis
Drug Approval | March 17, 2022

USFDA approves Rinvoq for ulcerative colitis

First approved in 2019, Rinvoq is a JAK inhibitor approved for four indications across gastroenterology, dermatology and rheumatology